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History lesson
In a recent review article, Spritz chronicled the accumulation 
of evidence for the genetic basis of vitiligo, a complex, 
multifactorial disease that involves white patches of skin 
and overlying hair resulting from autoimmune destruction 
of the melanocytes. Originally, premolecular studies high-
lighted a lack of complete Mendelian single-gene inheri-
tance. Subsequently, genetic linkage analysis of families with 
multiple affected relatives, candidate gene association stud-
ies comparing a relatively small number of cases, genome-
wide association studies, DNA sequencing studies, and gene 
expression studies have been performed. Indeed, extensive 
studies have unearthed a great wealth of information, and 36 
susceptibility genes have been identified with strong support. 
Approximately 90% of these genes are immunoregulatory in 
nature; the remaining 10% encode melanocyte proteins. These 
studies offer a hypothetical framework for conceptualization of 
vitiligo pathogenesis, including the initial triggering, immune 
propagation, and cytotoxicity of the antimelanocyte response, 
and provide potential new avenues for therapy and disease 
prevention in individuals with high genetic susceptibility. 
(J Dermatol 40:310–8, 2013) Selected by B. Gilchrest
Incomplete dissemination
Katz and Swetman recently penned a perspective to bring atten-
tion to the pitfalls of the Best Pharmaceuticals in Children Act, 
a piece of legislature signed into law in 2002 and made perma-
nent in 2012. As the major thrust of the federal government’s 
efforts to promote pediatric drug research, this law allows the 
US Food and Drug Administration to request pediatric studies of 
drugs, and in return, drug companies, which otherwise have lit-
tle financial incentive to conduct research with children, receive 
six-month marketing exclusivity extensions. The authors praise 
the research efforts that have stemmed from this act but high-
light the lack of a requirement for publication of such trials in 
peer-reviewed journals that are indexed in government-funded 
databases. The current situation therefore precludes widespread 
dissemination of important clinical results; as a result, ped-
iatric patients may be exposed to dangerous drugs that offer 
few proven effects, as in the case of imiquimod treatment for 
molluscum contagiosum. (Pediatrics, published online 24 June 
2013; doi:10.1542/peds.2013-0116) Selected by H. Williams
The power of two
Recently, inhibitors of mammalian target of rapamycin (mTOR) 
were introduced as a possible treatment strategy for tuberous 
sclerosis (TSC), a genetic disorder characterized by activation of 
mTOR and growth of benign tumors in various organs, includ-
ing skin, brain, and kidney. In a recent case report involving 
monozygotic twins, Kotulska and colleagues reported that the 
inhibitor everolimus was effective in preventing the develop-
ment of renal lesions, kidney cortical cysts, and facial angio-
fibromas in the treated twin girl. The drug was well tolerated, 
with minimal side effects and no apparent effects on growth 
during the follow-up period, and everolimus resulted in sig-
nificant clinical benefit, including the anticipated reduction in 
subependymal giant-cell astrocytoma tumor volume as well as 
prevention of the development of additional lesions. Because 
TSC symptoms result directly from organ and tissue malforma-
tions stemming from mTOR overactivity during early life, use of 
an mTOR inhibitor to prevent lesions seems feasible, warrant-
ing future investigation of this exciting possibility. (Pediatrics 
132:e239–42, 2013) Selected by T. Darling
Penicillin prophylaxis
Cellulitis of the lower leg commonly recurs, with new episodes 
causing damage to the lymphatic system and significant mor-
bidity. Currently, consensus-based guidelines for prevention 
of cellulitis involve prophylactic antibiotic therapy. The UK 
Dermatology Clinical Trials Network’s PATCH I trial team con-
ducted a double-blind, randomized controlled trial to examine 
the effectiveness of a 12-month course of low-dose penicillin for 
the prevention of cellulitis of the leg in patients with recurrent 
disease. This study revealed that low-dose prophylactic penicil-
lin nearly halved the risk of recurrence during the prophylaxis 
period, and treated patients had fewer recurrent episodes over 
the 3-year period than those receiving placebo, although the 
effect was lost by 36 months. Patients with a high body mass 
index, more than three episodes of cellulitis, or preexisting 
edema were less likely to reap the benefits of this prophylactic 
therapy. These results support the use of prophylactic penicil-
lin to prevent recurrent cellulitis, although the length of treat-
ment and dosage for specific populations warrant further study. 
(N Engl J Med 368:1695–703, 2013) Selected by T. Nijsten
New nails
Digit tip regeneration occurs in mammals following growth 
and differentiation of undifferentiated mesenchymal cells; 
however, inexplicably, no regeneration occurs when ampu-
tation is proximal to the nail bed. Takeo and colleagues dis-
covered that matrix cells enriched with nail stem cells (NSCs) 
downregulated the Wnt signaling pathway, which is involved 
in regulation of embryonic limb and nail development. In 
mice with disrupted Wnt signaling in the epithelium, nei-
ther nail nor bone regeneration was observed following digit 
amputation, suggesting that Wnt signaling is necessary for 
regeneration. Stabilization of β-catenin in the NSC region 
actually promoted regeneration, even following amputation 
proximal to the nail. Thus, NSCs undergo Wnt-mediated dif-
ferentiation to regulate nail and digit regeneration, and these 
findings may lead to novel treatment strategies for amputees. 
(Nature 499:228–32, 2013) Selected by M. AmagaiJournal of Investigative Dermatology (2013) 133, 2305. doi:10.1038/jid.2013.331
